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The aim of this study was to determine whether intranasal midazolam is a safe and effective rescue medication in adolescent
and adult patients with severe epilepsy.
This field trial was designed to test the feasibility of the use of intranasal midazolam as an alternative to rectal diazepam in a
cohort of patients with severe epilepsy who require rescue medication as part of their treatment. A dose of intranasal midazolam
(5 mg if the patient weighed less than 50 kg and 10 mg if the patient weighed over 50 kilograms) was prescribed for those
who had previously responded to other rescue medication. Midazolam was prescribed buccally if excessive head movement
accompanied seizures. The protocol reverted to the usual rescue medication if there was no response to midazolam within 10
minutes. Vital signs were monitored for half an hour following the administration of the treatment.
Twenty-two patients received 84 treatment episodes and 79 of these were considered clinically effective. Five treatment failures
were recorded, three due to poor technique in delivering the midazolam. Two patients were successfully retried on midazolam
and a third is awaiting a retrial of this drug. The two other treatment failures received the drug buccally. In the first patient the
clinical opinion was that this was possibly a psychogenic non-epileptic seizure. The other patient responded initially, but within
an hour had another seizure requiring further rescue treatment. No significant adverse effects were reported.
Our study shows that intranasal midazolam, when used appropriately, is an effective treatment in those who require rescue
treatment. There are clear advantages in the use of midazolam over diazepam in the treatment of acute seizures. These include
the favourable pharmacokinetic and pharmacodynamic properties of midazolam as well as the potential of a more acceptable
and dignified administration route.
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INTRODUCTION
Rescue medication plays an important role in the
management of epilepsy. It is prescribed for patients
with prolonged, repeated or cyanotic episodes during
seizures and for those with severe post-ictal aggres-
sion or agitation. These patients usually receive rectal
treatments including diazepam and paraldehyde. Rec-
tal diazepam, although the current treatment of choice,
has some significant drawbacks. The drug has a vari-
able absorption, is highly lipophilic and therefore has
a large volume of distribution leading to a half-life of
20–40 hours when administered rectally1. The rectal
route of administration has become unpopular because
of the undignified nature of the procedure. Changing
attitudes among some care organizations has compli-
cated this with some school and social service employ-
ees in the UK reticent about administering a drug via
the rectal route2.
Midazolam has recently been described as an al-
ternative rescue medication in severe epilepsy3–7. It
has a unique chemical structure which allows it to
be water soluble whilst in suspension and therefore
readily absorbed via the intranasal and buccal mu-
cosae. At physiological pH the ring structure closes
and the drug become lipid soluble allowing it to read-
ily cross the blood–brain barrier. Metabolism is princi-
pally via hepatic enzymes and the elimination half-life
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is 2 hours in healthy subjects8.
Previous studies using midazolam as an anaes-
thetic agent have concluded that the drug, when given
intranasally, is an effective sedative and amnestic
agent12–22. These studies have improved our under-
standing of the drug, the pros and cons of various
routes of administration and its pharmacodynamic and
pharmacokinetic properties12–22.
There are few reports confirming the efficacy of mi-
dazolam in terminating seizures4–7 and published data
on the safety of midazolam in epilepsy, particularly in
an adult population, is sparse3–11. For the small num-
ber of people with epilepsy who require rescue medi-
cation it is a potentially life saving treatment that may
significantly reduce morbidity and improve quality of
life. A field trial was undertaken to determine the effi-
cacy of intranasal midazolam as a rescue treatment in
epilepsy.
PATIENTS AND METHODS
Patients at a specialist Epilepsy Treatment Centre who
require rescue medication as part of their epilepsy
treatment were recruited to this study. The reasons
for rescue medication were prolonged or repeated
seizures, cyanotic events during seizures or disabling
post-ictal aggression or agitation. Most patients usu-
ally received rectal diazepam although some were re-
ceiving other treatments including rectal paraldehyde
or diazepam gel (for rectal use), administered buccally.
All patients, their carers or parents were provided
with an information leaflet detailing the unlicensed na-
ture of this treatment and references to available, pub-
lished data. Following discussions about the treatment,
the patient or legal guardian signed a consent or assent
to treatment form.
Patients acted as their own controls as all had pre-
viously responded to an alternative rescue treatment.
The protocol was designed so that intranasal midazo-
lam was prescribed as first line treatment and previ-
ous rescue medication was available as a fallback. The
need to use the previous rescue medication constituted
a trial failure. Possible problems with intranasal deliv-
ery were discussed and where indicated, for example
excessive head movements or upper respiratory tract
infections, it was agreed that a similar dose of mida-
zolam could be administered buccally.
A qualified nurse administered the first dose of mi-
dazolam and monitored vital signs for 30 minutes, giv-
ing the fallback medication in the event of treatment
failure. The delivery method altered slightly during the
trial period. Initially the drug was drawn up with a sy-
ringe and needle and then administered via a neonatal
feeding tube or the tubing of a butterfly needle with the
needle removed. This method was found to be cum-
bersome and was further complicated by the presence
of various sharp objects. The administration protocol
was therefore modified to allow the use of a 1 ml Pas-
teur pipette (made of disposable soft plastic), the dose
remained unchanged.
The usual recommended dose for intravenous ad-
ministration of midazolam in children is 0.2 mg kg−1.
The proprietary vial of this preparation contains 2 ml
of a 5 mg ml−1 concentration. In order to simplify
the administration process, all patients weighing over
50 kg received 10 ml and those weighing less than
50 kg received 5 ml as a starting dose. Because of their
physical characteristics, one patient received 20 mg
after an initial treatment failure, this dose was effec-
tive and subsequent treatments with the Pasteur pipette
were successful at a dose of 10 mg.
The majority of patients received rescue medication
for generalized tonic–clonic seizures, but it was also
used in some patients with complex partial or my-
oclonic seizures (refer to Table 1).
RESULTS
Twenty-two patients (13 male and 9 female), ranging
in age from 12–72 (median 26) have received 84 doses
of midazolam as rescue medication. Patients were ex-
periencing between 1 and 250 seizures a month.
There were five treatment failures in this study.
Three treatment episodes in three different patients
failed due to poor technique in delivering an adequate
intranasal dose of the drug. Two of these patients have
had more than one treatment and have subsequently re-
sponded using the new administration protocol whilst
the other is awaiting an opportunity to be retried. All
these received rectal diazepam after 10 minutes with
good effect.
Two treatments were given via the buccal route; both
resulted in treatment failure. Both patients received
this treatment because of excessive head movements
during the seizure. In the first of these treatment fail-
ures, the seizure was retrospectively considered by
staff to be non-epileptic and psychogenic in nature.
The other responded initially with termination of the
seizure, but recurrence within the hour required fur-
ther rescue medication and the fallback treatment was
given. There were no recorded abnormalities in blood
pressure or pulse and no apnoea or diminished respira-
tory effort following the administration of midazolam.
DISCUSSION
Prolonged, repeated or cyanotic episodes during
seizures were the most common reasons for prescrib-
ing rescue medication and in this study 58 of the
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Table 1: Patients receiving intranasal or buccal midazolam.
No Age Sex Classification/Syndrome Dose No of Reason for Failures
(mg) doses treatment
1 12 M Lennox Gastaut 10 1 Prolonged
2 13 M Generalized 5 6 Cyanotic
3 14 F Localization related 5 9 Cyanotic
4 16 F Lennox Gastaut 10 2 Prolonged
5 16 M Generalized 10 1 Aggression
6 16 M Generalized 10 1 Clusters X
7 19 F Localization related 10 3 Clusters
8 20 M Localization related 10a 13 Prolonged X
9 21 M Generalized 10 6 Cyanotic
10 25 M Localization related 10 1 Prolonged
11 25 M Generalized 10 3 Agitation X
12 27 F Localization related 10 2 Prolonged Xb
13 31 M Localization related 10 2 Clusters
14 34 F Generalized 10 22 Agitation
15 35 M Localization related 10 1 Clusters
16 43 M Localization related 10 1 Prolonged
17 44 F Generalized 10 1 Prolonged
18 47 F Generalized 10 2 Clusters
19 47 M Generalized 10 1 Clusters
20 52 M Localization related 10 1 Prolonged
21 56 F Localization related 10 4 Prolonged Xb
22 72 F Generalized 10 1 Cyanotic
a Has also received one dose of 20 mg. b Received buccal midazolam.
Table 2: Reason for treatment and outcome.
Reason for treatment Number of patients Number of treatments Failures in each group
Cyanotic episodes 4 22 0
Clusters of seizures 6 10 1
Prolonged seizures 9 26 3
Post-ictal events 3 26 1
84 treatments (69%) fell within this group. There
were no treatment failures in the group with cyan-
otic episodes. The three treatment failures in the pro-
longed seizure group comprised two where the failure
was attributed to poor technique and one due to a psy-
chogenic non-epileptic attack.
The authors were concerned that the short duration
of action of midazolam would make it an inappro-
priate drug for the treatment of seizure clusters (re-
peated seizures) where there is full recovery between
seizures. No defining criteria were set for seizure clus-
tering other than a past history and routine use of res-
cue medication to prevent this occurring. Apart from
one treatment episode, this medication appeared to
successfully prevent seizure clustering in patients with
a history of these episodes. It may be argued that in
some patients rescue medication may not have been
required, but for those patients included in the study,
clustering remained a typical occurrence and rescue
medication part of their routine treatment protocol.
The protocol for most patients required rescue treat-
ment after the second seizure.
The one treatment failure in this group may indicate
that in the event of breakthrough seizures within an
hour, alternative longer-acting medication may be re-
quired. A suggested protocol would be to treat the first
episode with midazolam and to then use an oral dose
of a longer-acting benzodiazepine if the patient was to
regularly experience further seizures.
Some patients with short-lived major seizures may
experience severe post-ictal aggression or agitation
that requires medication. Three individuals who suf-
fered from debilitating post-ictal events received 26 of
the 84 treatments (31%). There was one treatment fail-
ure in this group believed to be due to poor technique.
The rapid action of midazolam without prolonged ef-
fect has resulted in a successful alternative to the more
sedating and longer-acting oral or rectal medication
previously prescribed.
Patients in this group are often extremely embar-
rassed or remorseful when they discover the results of
their behaviour. They often have shorter seizures, but
a protracted post-ictal period. It is essential to deliver
medication very rapidly and for the medication to have
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Fig. 1: Original administration devices: 2 ml syringe, neonatal feeding tube and butterfly needle tubing with the needle removed.
Fig. 2: Pasteur pipette (1 ml) with midazolam vial (2 ml).
a rapid onset of effect. Our experience is that this treat-
ment has been extremely successful in preventing such
episodes (in a limited number of patients with a long
history of this disorder) with a dramatic improvement
in post-ictal behaviour.
Midazolam has an acidic pH (3.28) and therefore is
a potential irritant, which it is suggested may cause
discomfort when used intranasally23. We can report
that in our cohort of patients, who are aged 12 years
and older, on questioning none have experienced or
complained of debilitating effects.
Some patients who experience simple or complex
partial seizures have had interictal trials of intranasal
saline solution in order to acclimatize them to this
route of delivery. Early reports suggest that they have
tolerated this route of administration and can possi-
bly be given intranasal midazolam despite no loss of
awareness during partial seizures. This raises the pos-
sibility of self-administration of midazolam in order to
prevent seizure progression for some patients.
The patients included in this study are now all pre-
scribed midazolam as first line rescue treatment on
a named patient basis. Having improved the delivery
method via a 1 ml disposable plastic Pasteur pipette,
non-professionally trained care staff and parents have
successfully used this treatment method.
Rescue medication has an important place in the
treatment of severe epilepsy. Intranasal midazolam ap-
pears to be a safe and effective rescue treatment that
has a number of advantages over rectal diazepam.
Nasal treatment is more dignified and more accept-
able to both patients and carers. Midazolam has
more favourable pharmacokinetic and pharmacody-
namic properties resulting in a rapid onset of action
without accumulation and subsequent ‘hangover’ ef-
fect. Further benefit has been derived for the patients
in this study through the apparent lessening of hand-
icap by improving access to education, employment
and social opportunities due to the rapid onset of ac-
tion and quick recovery.
This field trail confirms that intranasal midazolam is
effective at terminating prolonged seizures, preventing
seizure clustering and avoiding post-ictal behavioural
complications in adolescent and adult patients with se-
vere epilepsy. The intranasal route has been demon-
strated to be accessible, acceptable and apparently free
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of adverse experiences and complications. Further-
more, non-trained care staff have successfully admin-
istered the treatment. Although no adverse experiences
have been reported to date, the sample sizes in this and
other studies remain too small to be certain of safety
especially with prolonged, repeated use. Further multi-
centre studies are required in order to reach consensus
for the future use of what is currently an unlicensed
delivery route and treatment for epilepsy.
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